| Advanced Vision Center Pllc | |
|
705 Sawmill Rd, Laurel, MS 39440-3937 | |
| (601) 649-2450 | |
| (601) 649-0556 |
| Full Name | Advanced Vision Center Pllc |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 705 Sawmill Rd, Laurel, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538341839 | NPI | - | NPPES |
| 200001782 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | John B Lyon |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1336208305 PECOS PAC ID: 0749178416 Enrollment ID: I20050610000060 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
Scioderm announced its investigational product SD-101 has received Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of patients with inherited Epidermolysis Bullosa.
Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.
Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
› Verified 8 days ago
| Provider Name | Jennifer L Dooley |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1568832483 PECOS PAC ID: 6305190950 Enrollment ID: I20181116001879 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
Scioderm announced its investigational product SD-101 has received Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of patients with inherited Epidermolysis Bullosa.
Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.
Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Advanced Vision Center Pllc Po Box 1965, Laurel, MS 39441-1965 Ph: (601) 649-2450 | Advanced Vision Center Pllc 705 Sawmill Rd, Laurel, MS 39440-3937 Ph: (601) 649-2450 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
Scioderm announced its investigational product SD-101 has received Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of patients with inherited Epidermolysis Bullosa.
Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.
Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
› Verified 8 days ago